- Disease: Acute COVID-19
- Study type: Observational Cohort Study, Treatment
- Study type descriptors: Prospective, Single centre
- Objective: To describe remdesivir’s safety profile and patient outcomes in a subset of high-risk haematological patients treated with more than 10 days of remdesivir in the Omicron era
- Number of participants enrolled: 18
- Study enrolling from to
- Study includes follow-up for 1 month
Study Data
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Remdesivir
External Links
Other information
Funders/Sponsors:
- Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse
- Collège des Universitaires de Maladies Infectieuses et Tropicales
- Ministerio de Sanidad y Consumo
- Agencia de Gestión de Ayudas Universitarias y de Investigación (AGAUR) of Catalunya
- Instituto de Salud Carlos III
- European Union
The information was provided with the aid of the study investigators
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to